Beldio Research GmbH
- Address
- lock Available on a paid plan
Immune System Diseases
At Beldio Research GmbH in Memmingen, the clinical program in immune system diseases focuses on inflammatory conditions such as psoriasis and hidradenitis suppurativa. These studies are designed to assess how well new and existing therapies control symptoms, improve skin outcomes, and maintain longer-term safety.
- Testing new treatment options for moderate-to-severe plaque psoriasis
- Evaluating therapies for hidradenitis suppurativa in adults and adolescents
- Assessing long-term safety and treatment effectiveness in chronic inflammatory skin disease
The research includes comparisons of active treatments and placebo to better understand symptom relief, disease control, and overall tolerability in people living with these immune-mediated disorders.
Skin and Connective Tissue Diseases
The site also supports studies in skin and connective tissue diseases, with a strong emphasis on vitiligo, chronic venous ulcers, and plaque psoriasis. This work aims to improve healing, restore skin appearance, and identify therapies that can offer more consistent benefit across different patient groups.
- Investigating treatment approaches for nonsegmental vitiligo
- Studying wound healing in chronic venous ulcers
- Exploring better symptom control in plaque psoriasis
These trials are centered on both symptom improvement and safety, helping clarify which therapies may be most useful for persistent skin conditions that can affect daily life and long-term quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novartis Pharma AG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Beldio Research GmbH
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAD328 in Adults with Moderate to Severe Hidradenitis Suppurativa | Almirall S.A. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide | 2 | Unknown | 2023-06-15 | 2024-07-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.